Scancell Funds a Phase 3 Melanoma Bet

Company Scancell / Neuphoria Therapeutics Event Type Reverse Merger + Financing (Deal & Financing) Modality DNA Immunotherapy (ImmunoBody Platform) Platform iSCIB1+ Indication Advanced Melanoma Summary Scancell agreed to acquire Nasdaq-listed Neuphoria in an all-share reverse merger and arranged up to $89 million of associated equity,…